Tag: investors

MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompanying Series A Warrants and accompanying Series B warrants. All securities to be sold in the Offering will be sold by Milestone. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

FirstFarms will have the opportunity to apply for subsidy for investments in animals and to cover other costs in relation to the outbreak of foot and mouth disease that was detected at the company's farm in Plavecky Stvrtok, Slovakia, on 30 March this year. 3,521 animals were subsequently culled.

SHREWSBURY, United Kingdom, July 10, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a next-generation Layer 1 blockchain built for AI-powered applications, today announced the launch of its Bonus Round, marking a significant milestone after successfully closing all 15 presale stages with $21.1 million in total contributions. As part of its next phase of ecosystem expansion, Lightchain AI has officially rolled out its staking infrastructure and launched a $150,000 developer grant program to support dApp development and community innovation.

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zynex, Inc. (NASDAQ:ZYXI) on behalf of long-term stockholders following a class action complaint that was filed against Zynex on July 9, 2025 with a Class Period from March 13, 2023, to the present. Our investigation concerns whether the board of directors of Zynex have breached their fiduciary duties to the company.